Hydroxyurea treatment in β-thalassemia patients: To respond or not to respond?

Annals of Hematology

Volumn 92, Issue 3, 2013, Pages 289-299

  Banan, Mehdi ^a  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

Author keywords

thalassemia; HbF; Hydroxyurea; Pharmacogenomics

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; NEURONAL NITRIC OXIDE SYNTHASE; PROTEIN MYB; VASCULOTROPIN RECEPTOR 1;

ARG1 GENE; ARG2 GENE; BCL11A GENE; BETA THALASSEMIA; DIZZINESS; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SENSITIVITY; ERYTHROPOIESIS; FLT1 GENE; GENE; GENE ACTIVATION; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HBS1L MYB GENE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN SYNTHESIS; HPFH GENE; HUMAN; HYPERPIGMENTATION; INTRACELLULAR SIGNALING; LEG ULCER; LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; NOS1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE TRAIT LOCUS; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SPERMATOGENESIS; TOX GENE; TREATMENT RESPONSE; XMNI GENE;

ANIMALS; BETA-THALASSEMIA; ENZYME INHIBITORS; HUMANS; HYDROXYUREA; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84873990028     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1671-3     Document Type: Review

References (110)

1. Forget BG, Hardison RC (2009) The normal structure and regulation of human globin gene clusters. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin, 2nd edn. Cambridge University Press, New York, pp 46-61
2. Bank A (2005) Understanding globin regulation in β-thalassemia: it's as simple as α, β, γ, δ. J Clin Invest 115(6):1470-1473
3. Bank A (2006) Regulation of human fetal hemoglobin: new players, new complexities. Blood 107(2):435-443
4. Stamatoyannopoulos G, Navas PA, Li Q (2009) Molecular and cellular basis of hemoglobin switching. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin, 2nd edn. Cambridge University Press, New York, pp 86-100
5. Rund D, Rachmilewitz E (2005) β-thalassemia. N Engl J Med 353(11):1135-1146
6. Weatherall D (2001) Thalassemias. In: Encyclopedia of Life Sciences. Wiley, Chichester
7. Thein SL, Wood WG (2009) The molecular basis of β thalassemia, δβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin, 2nd edn. Cambridge University Press, Cambridge, pp 323-356
8. Weatherall DJ (2001) Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2(4):245-255
9. Thein SL (2005) Genetic modifiers of β-thalassemia. Haematologica 90(5):649-660
10. Patrinos GP, Kollia P, Papadakis MN (2005) Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum Mutat 26(5):399-412
11. Perrine SP (2005) Fetal globin induction: can it cure β thalassemia? Hematology 2005(1):38-44
12. Aγ-globin gene in transgenic mice. J Biol Chem 270(17):10256-10263
13. Elder JT, Forrester WC, Thompson C, Mager D, Henthorn P, Peretz M, Papayannopoulou T, Groudine M (1990) Translocation of an erythroid-specific hypersensitive site in deletion-type hereditary persistence of fetal hemoglobin. Mol Cell Biol 10(4):1382-1389
14. Xiang P, Han H, Barkess G, Olave I, Fang X, Yin W, Stamatoyannopoulos G, Li Q (2005) Juxtaposition of the HPFH2 enhancer is not sufficient to reactivate the γ-globin gene in adult erythropoiesis. Hum Mol Genet 14(20):3047-3056
15. Sankaran VG, Xu J, Byron R, Greisman HA, Fisher C, Weatherall DJ, Sabath DE, Groudine M, Orkin SH, Premawardhena A, Bender MA (2011) A functional element necessary for fetal hemoglobin silencing. N Engl J Med 365(9):807-814
16. Ghedira ES, Lecerf L, Faubert E, Coste B, Moradkhani K, Bachir D, Galacteros F, Pissard S (2013) Estimation of the difference in HbF expression due to loss of the 5′ δ-globin BCL11A binding region. Haematologica (in press)
17. Testa U (2009) Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 88(6):505-528
18. Atweh GF, DeSimone J, Saunthararajah Y, Fathallah H, Weinberg RS, Nagel RL, Fabry ME, Adams RJ (2003) Hemoglobinopathies. Hematology 2003(1):14-39
19. Ataga KI (2009) Novel therapies in sickle cell disease. Hematology 2009(1):54-61
20. Migliaccio AR, Rotili D, Nebbioso A, Atweh G, Mai A (2008) Histone deacetylase inhibitors and hemoglobin F induction in β-thalassemia. Int J Biochem Cell Biol 40(11):2341-2347
21. Saunthararajah Y, Atweh GF (2009) Induction of fetal hemoglobin in the treatment of sickle cell disease and β thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin, 2nd edn. Cambridge University Press, New York, pp 745-754
22. Krakoff IH, Brown NC, Reichard P (1968) Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28(8):1559-1565
23. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr, Platt OS (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79(10):2555-2565
24. Steinberg MH, Lu Z-H, Barton FB, Terrin ML, Charache S, Dover GJ, the Multicenter Study of H (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 89(3):1078-1088
25. Steinberg MH (2002) Hydroxyurea treatment for sickle cell disease. Sci World J 2:1706-1728
26. Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358(13):1362-1369
27. Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R (2009) Hydroxyurea in sickle cell disease-a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis 42(1):25-31
28. Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, Rodgers GP (1995) Hydroxyurea therapy in β-thalassaemia intermedia: improvement in haematological parameters due to enhanced β-globin synthesis. Br J Haematol 90(3):557-563
29. Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP (1996) Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease. Blood 87(3):887-892
30. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M (2003) Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 102(4):1529-1530
31. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P (2004) Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol 83(7):430-433
32. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC (2004) Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica 89(10):1172-1178
33. Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP (2005) Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol 84(7):441-446
34. Watanapokasin Y, Chuncharunee S, Sanmund D, Kongnium W, Winichagoon P, Rodgers GP, Fucharoen S (2005) In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in β-thalassemia/hemoglobin E patients. Exp Hematol 33(12):1486-1492
35. Watanapokasin R, Sanmund D, Winichagoon P, Muta K, Fucharoen S (2006) Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients' peripheral blood erythroid cell culture. Ann Hematol 85(3):164-169
36. Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M (2007) Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 47(10):1830-1836
37. Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T (2007) Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having β-thalassemia major: Karachi HU trial (KHUT). J Pediatr Hematol Oncol 29(11):743-746
38. Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H (2008) Response to hydroxyurea therapy in β-thalassemia. Am J Hematol 83(5):366-370
39. Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB (2009) Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin Chim Acta 407(1-2):10-15
40. Karimi M, Haghpanah S, Farhadi A, Yavarian M (2012) Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol 95(1):51-56
41. Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, Bayat N, Khani MH, Neishabury M, Najmabadi H (2012) The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin 36(4):371-380
42. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II Trial. Blood 94(5):1550-1554
43. McGann PT, Ware RE (2011) Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol 18(3):158-165
44. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289(13):1645-1651
45. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 148(12):939-955
46. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95(11):3589-3593
47. Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kheradmand Kia S, Esteghamat F, van Ijcken W, Philipsen S, Najmabadi H, Grosveld F (2013) Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica (in press)
48. Mabaera R, West RJ, Conine SJ, Macari ER, Boyd CD, Engman CA, Lowrey CH (2008) A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol 36(9):1057-1072
49. Philipsen S, Wood WG (2009) Erythropoiesis. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin, 2nd edn. Cambridge University Press, Cambridge, pp 24-45
50. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG (1984) Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 310(14):869-873
51. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Miller BA, Nathan DG (1985) Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest 75(6):1999-2005
52. Miller BA, Platt O, Hope S, Dover G, Nathan DG (1987) Influence of hydroxyurea on fetal hemoglobin production in vitro. Blood 70(6):1824-1829
53. Mankad VN, Baliga S, Phillips K, Shah AK, Yang YM (1994) Relationship of burst-forming-unit-erythroid progenitors and their DNA-synthesis stage to fetal hemoglobin levels in hydroxyurea-treated patients with sickle cell anemia. Am J Hematol 46(4):259-263
54. Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE (2012) Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol 157(2):240-248
55. Wang M, Tang DC, Liu W, Chin K, Zhu JG, Fibach E, Rodgers GP (2002) Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 119(4):1098-1105
56. Weiss MJ, Orkin SH (1995) Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci USA 92(21):9623-9627
57. Drexler HG, Matsuo Y, MacLeod RA (2004) Malignant hematopoietic cell lines: in vitro models for the study of erythroleukemia. Leuk Res 28(12):1243-1251
58. Erard F, Dean A, Schechter AN (1981) Inhibitors of cell division reversibly modify hemoglobin concentration in human erythroleukemia K562 cells. Blood 58(6):1236-1239
59. Tang DC, Zhu J, Liu W, Chin K, Sun J, Chen L, Hanover JA, Rodgers GP (2005) The hydroxyurea-induced small GTP-binding protein SAR modulates γ-globin gene expression in human erythroid cells. Blood 106(9):3256-3263
60. Fibach E, Burke KP, Schechter AN, Noguchi CT, Rodgers GP (1993) Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood 81(6):1630-1635
61. Smith RD, Li J, Noguchi CT, Schechter AN (2000) Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 95(3):863-869
62. Walker AL, Franke RM, Sparreboom A, Ware RE (2011) Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol 39(4):446-456
63. Pacelli R, Taira J, Cook JA, Wink DA, Krishna MC (1996) Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 347(9005):900
64. Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN (2008) Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 111(3):1117-1123
65. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111(2):231-239
66. Ikuta T, Ausenda S, Cappellini MD (2001) Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci USA 98(4):1847-1852
67. Cokic VP, Schechter AN (2008) Effects of nitric oxide on red blood cell development and phenotype. In: Bieker JJ (ed) Red cell development, vol. 82. Elsevier, Amsterdam, pp. 169-200
68. Beavo JA, Hansen RS, Harrison SA, Hurwitz RL, Martins TJ, Mumby MC (1982) Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol 28(3):387-410
69. + cells. Exp Hematol 34(9):1151-1161
70. Kuroyanagi Y, Kaneko Y, Muta K, Park BS, Moi P, Ausenda S, Cappellini MD, Ikuta T (2006) cAMP differentially regulates γ-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem Biophys Res Commun 344(3):1038-1047
71. Ramakrishnan V, Pace BS (2011) Regulation of γ-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway. Blood Cells Mol Dis 47(1):12-22
72. Park J-I, Choi H-S, Jeong J-S, Han J-Y, Kim I-H (2001) Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. Cell Growth Differ 12(9):481-486
73. Sangerman J, Lee MS, Yao X, Oteng E, Hsiao C-H, Li W, Zein S, Ofori-Acquah SF, Pace BS (2006) Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by CREB1 and ATF-2. Blood 108(10):3590-3599
74. Gγ-globin gene expression via an upstream cAMP response element. Blood Cells Mol Dis 44(1):7-15
75. Banan M, Esmaeilzadeh-Ghar E, Nezami M, Deilami Z, Farashi S, Philipsen S, Esteghamat F, Pourfarzad F, Ali Imam AM, Najmabadi H (2012) cAMP response element-binding protein 1 is required for hydroxyurea-mediated induction of γ-globin expression in K562 cells. Clin Exp Pharmacol Physiol 39(6):510-517
76. Banan M, Puri N (2004) The ins and outs of RNAi in mammalian cells. Curr Pharm Biotechnol 5(5):441-450
77. Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang Y-D, Ware RE (2011) Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood 118(20):5664-5670
78. Green NS, Barral S (2010) Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr Blood Cancer 56(2):177-181
79. Menzel S, Thein SL (2009) Genetic architecture of hemoglobin F control. Curr Opin Hematol 16(3):179-186
80. Labie D, Dunda-Belkhodja O, Rouabhi F, Pagnier J, Ragusa A, Nagel RL (1985) The -158 site 5′ to the Gγ gene and Gγ expression. Blood 66(6):1463-1465
81. Gilman JG, Huisman TH (1985) DNA sequence variation associated with elevated fetal Gγ globin production. Blood 66(4):783-787
82. Gγ-globin gene expression and high Hb F levels in β-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci USA 82(7):2111-2114
83. Lettre G, Sankaran VG, Bezerra MAC, Araujo AS, Uda M, Sanna S, Cao A, Schlessinger D, Costa FF, Hirschhorn JN, Orkin SH (2008) DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 105(33):11869-11874
84. Garner C, Tatu T, Reittie JE, Littlewood T, Darley J, Cervino S, Farrall M, Kelly P, Spector TD, Thein SL (2000) Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 95(1):342-346
85. Badens C, Joly P, Agouti I, Thuret I, Gonnet K, Fattoum S, Francina A, Simeoni M-C, Loundou A, Pissard S (2011) Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica 96(11):1712-1714
86. Danjou F, Anni F, Galanello R (2011) β-thalassemia: from genotype to phenotype. Haematologica 96(11):1573-1575
87. Banan M, Bayat H, Namdar P, Azarkeivan A, Kamali K, Daneshmand P, Zaker B, Najmabadi H (2013) Utility of the multivariate approach in predicting the β-thalassemia intermedia or major types in Iranian patients. Hemoglobin (in press)
88. Thein SL (2004) Genetic insights into the clinical diversity of β thalassaemia. Br J Haematol 124(3):264-274
89. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HKA, Hirschhorn JN, Cantor AB, Orkin SH (2008) Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322(5909):1839-1842
90. Chen Z, Luo HY, Steinberg MH, Chui DH (2009) BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 42(2):144-149
91. Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, Bender MA, Tucker PW, Orkin SH (2009) Developmental and species-divergent globin switching are driven by BCL11A. Nature 460(7259):1093-1097
92. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, Tucker PW, Orkin SH (2011) Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334(6058):993-996
93. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai G, Piras MG, Sestu N, Lai S, Dei M, Mulas A, Crisponi L, Naitza S, Asunis I, Deiana M, Nagaraja R, Perseu L, Satta S, Cipollina MD, Sollaino C, Moi P, Hirschhorn JN, Orkin SH, Abecasis GR, Schlessinger D, Cao A (2008) Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci USA 105(5):1620-1625
94. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G (2010) Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 42(12):1049-1051
95. Gγ polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β-thalassemia intermedia patients. Blood Cells Mol Dis 45(2):124-127
96. Sedgewick AE, Timofeev N, Sebastiani P, So JC, Ma ES, Chan LC, Fucharoen G, Fucharoen S, Barbosa CG, Vardarajan BN, Farrer LA, Baldwin CT, Steinberg MH, Chui DH (2008) BCL11A is a major HbF quantitative trait locus in three different populations with β-hemoglobinopathies. Blood Cells Mol Dis 41(3):255-258
97. Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, Keefer JR (2011) Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. J Hum Genet 56(4):316-323
98. o thalassemia by genetic modifiers. Blood 114(18):3935-3937
99. Bauer DE, Xu J, Fujiwara Y, Stamatoyannopoulos JA, Orkin SH (2011) Functional evaluation of HbF-associated region of BCL11A locus. Blood (ASH Annual Meeting Abstracts) 118(21):2148
100. Wahlberg K, Jiang J, Rooks H, Jawaid K, Matsuda F, Yamaguchi M, Lathrop M, Thein SL, Best S (2009) The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 114(6):1254-1262
101. Creary LE, Ulug P, Menzel S, McKenzie CA, Hanchard NA, Taylor V, Farrall M, Forrester TE, Thein SL (2009) Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One 4(1):e4218
102. Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector TD, Thein SL (2006) cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108(3):1077-1083
103. Sankaran VG, Menne TF, Scepanovic D, Vergilio J-A, Ji P, Kim J, Thiru P, Orkin SH, Lander ES, Lodish HF (2011) MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA 108(4):1519-1524
104. Farrell JJ, Sherva RM, Chen Z-y, Luo H-y, Chu BF, Ha SY, Li CK, Lee ACW, Li RCH, Li CK, Yuen HL, So JCC, Ma ESK, Chan LC, Chan V, Sebastiani P, Farrer LA, Baldwin CT, Steinberg MH, Chui DHK (2011) A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood 117(18):4935-4945
105. Stadhouders R, Thongjuea S, Andrieu-Soler C, Palstra RJ, Bryne JC, van den Heuvel A, Stevens M, de Boer E, Kockx C, van der Sloot A, van den Hout M, van Ijcken W, Eick D, Lenhard B, Grosveld F, Soler E (2012) Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development. EMBO J 31(4):986-999
106. Kumkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers GP (2008) Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol 141(2):254-259
107. Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH (2007) Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J 7(6):386-394
108. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A (2011) Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118(18):4985-4991
109. Vasavda N, Woodley C, Allman M, Drasar E, Awogbade M, Howard J, Thein SL (2012) Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids. Br J Haematol 157(2):249-252
110. Chan KSK, Xu J, Wardan H, McColl B, Orkin S, Vadolas J (2012) Generation of a genomic reporter assay system for analysis of γ- and β-globin gene regulation. FASEB J 26(4):1736-1744